US20020028486A1 - Antibodies having modified carbohydrate content and methods of preparation and use - Google Patents
Antibodies having modified carbohydrate content and methods of preparation and use Download PDFInfo
- Publication number
- US20020028486A1 US20020028486A1 US09/835,461 US83546101A US2002028486A1 US 20020028486 A1 US20020028486 A1 US 20020028486A1 US 83546101 A US83546101 A US 83546101A US 2002028486 A1 US2002028486 A1 US 2002028486A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- carbohydrate
- recognition site
- carbohydrate recognition
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001720 carbohydrates Chemical class 0.000 title claims abstract description 163
- 238000000034 method Methods 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title description 2
- 239000000126 substance Substances 0.000 claims abstract description 42
- 239000000427 antigen Substances 0.000 claims abstract description 19
- 102000036639 antigens Human genes 0.000 claims abstract description 19
- 108091007433 antigens Proteins 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 5
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 4
- 239000003446 ligand Substances 0.000 claims description 13
- 238000002741 site-directed mutagenesis Methods 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 7
- 239000012636 effector Substances 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000004445 quantitative analysis Methods 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 description 122
- 229920002307 Dextran Polymers 0.000 description 38
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 20
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 20
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 20
- 108010062580 Concanavalin A Proteins 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- YGMBQDCBGPAZNW-YIBJATESSA-N (2r,3s,4r,5r)-2-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4,5,6-tetrakis[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]hexanal Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@H]([C@@H](O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@H](O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H](O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C=O)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YGMBQDCBGPAZNW-YIBJATESSA-N 0.000 description 6
- -1 Asn amino acid Chemical class 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 229940099472 immunoglobulin a Drugs 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000004988 N-glycosylation Effects 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 150000002482 oligosaccharides Chemical class 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 231100000219 mutagenic Toxicity 0.000 description 4
- 230000003505 mutagenic effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- MSWZFWKMSRAUBD-BMEPZIPPSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)(214C)oxane-2,4,5-triol Chemical compound O[14CH]1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-BMEPZIPPSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000010807 negative regulation of binding Effects 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009830 antibody antigen interaction Effects 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000013198 immunometric assay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000005717 Myeloma Proteins Human genes 0.000 description 1
- 108010045503 Myeloma Proteins Proteins 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- PLJAKLUDUPBLGD-VLWZLFBZSA-N N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-aldehydo-D-glucosamine Chemical compound CC(=O)N[C@@H](C=O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O PLJAKLUDUPBLGD-VLWZLFBZSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002761 liquid phase assay Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Definitions
- the carbohydrate content of an antibody may be modified by adding or deleting carbohydrate recognition sites in the constant region of the antibody. In so doing, effector functions of the antibody are modified.
- Carbohydrate recognition sites in the constant region can also serve as sites for labelling, e.g., radionuclides, such as 125 I.
- This invention concerns a method of altering the affinity of an antibody for the antigen to which it is directed which comprises introducing into the variable region of the antibody a carbohydrate recognition site under conditions such that a carbohydrate binds to the site and thus attaches to the antibody.
- This invention also concerns a method of producing an antibody which may be more readily recovered or purified which comprises introducing into the variable region of the antibody a carbohydrate recognition site under conditions such that a carbohydrate binds to the site and thus attaches to the antibody.
- This invention further provides an antibody which does not occur in nature and which comprises a carbohydrate recognition site genetically engineered into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region.
- the present invention provides a method of modifying the carbohydrate content of an antibody which comprises deleting from a constant region of the antibody a carbohydrate recognition site which naturally occurs in such constant region of such antibody.
- the invention also provides a method of modifying the carbohydrate content of an antibody which comprises adding to a constant region of the antibody a carbohydrate recognition site which does not naturally occur in such constant region of such antibody.
- This invention further concerns a human antibody which does not occur in nature and which is characterized by the absence of a carbohydrate recognition site in a constant region of the antibody which naturally includes such a carbohydrate recognition site in such constant region.
- this invention provides a human antibody which does not occur in nature and which is characterized by the presence of a carbohydrate recognition site in a constant region of the antibody which does not naturally include such a carbohydrate recognition site in such constant region.
- this invention provides therapeutic agents derived from, and DNA encoding, the antibodies, of the invention as well as sensitive methods for detecting the presence of substances in a sample, methods for recovering a substance from a sample containing the substance and for purifying such substance, and diagnostic test kits.
- FIG. 1 Substitution of the genomic V H region with V H cDNA and isotype switch.
- a genomic EcoRI fragment containing the MPC11 H chain promoter, leader sequence, rearranged V region, and Ig enhancer (22) was cloned into the EcoRI site of a pBR322 derivative deleted of nucleotide 2065 through 29.
- the V region of MPC11 was replaced by the anti-dextran V region by inserting the PvuII-PstI cDNA fragment into PvuII-PstI cleaved MPC11.
- the first four V H amino acids are derived from MPC11, but are identical to those found in the three cDNAs (22).
- the EcoRI fragment containing the dextran V H was joined to a human IgG 4 constant region within the pSV2-gpt expression vector (23, 4).
- the coding sequences of the MPC11 and cDNA genes are shown as solid and hatched lines, respectively.
- the dotted boxes represent the coding sequences of the human IgG 4 constant region.
- the maps are not drawn to scale.
- FIG. 2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of immunoprecipitates obtained after papain digestion of A) [ 35 S]-Met or B) [ 14 C]-glucosamine labelled secreted Ig.
- Secretions of cells labelled in the presence of 15 micro Ci/ml of [ 35 S]-Met or 100 micro Ci/mi [ 14 C]-D-glucosamine hydrochloride (24) were digested with papain (Sigma Chemical Co., St. Louis, Mo.) at 1:100 enzyme:protein ratio for four hours at 37° C. The reaction was stopped by addition of iodoacetamide to 0.03 M.
- the Fc fraction and undigested antibody protein were precipitated by incubation with IgG Sorb (Enzyme Center, Malden, Mass.).
- Antigen binding fragment (Fab) was precipitated from the supernatant using rabbit anti-human Fab or by insolubilized dextran (Sephadex® G75). Samples were reduced with beta-mercaptoethanol. (0.15 M) and analyzed using 5% SDS-PAGE (16).
- the heavy chains produced by the transfectant cell lines are as follows: THV8, V H 19.22.1; TJC8.5, V H 5.54.4.24.1; TKC3.2, V H 14.6b.1; all transfectants synthesize the alpha (1 ⁇ 6) dextran specific light chain. [ 35 S]-Met labelled and reduced Igs were used as markers.
- the TKC3.2 (Fab) and TKC3.2 samples were analyzed on a separate SDS-PAGE gel.
- FIG. 3 12.5% Tris-glycine SDS-PAGE analysis of [ 35 S]-Met labelled transfectoma culture supernatants, immunoprecipitated with rabbit anti-human Ig fragment constant region (Fc) antiserum following Concanavalin A (Con A) adsorption (as indicated) and/or tunicamycin treatment. Tunicamycin at a concentration of 8 micrograms/ml (Boehringer Mannheim, West Germany) was used to inhibit N-Linked glycosylation.
- Con A sepharose adsorption of secreted transfectoma Ig.
- 3B Tunicamycin treated cell supernatants without or with Con A—Sepharose adsorption. Lanes 1 and 2, TKC3.2 (V H 14.6b.1) before and after tunicamycin treatment; lanes 3 and 4, THV8.3 (V H 19.22.1) before and after tunicamycin treatment; lanes 5 and 6, tunicamycin treated TKC3.2 Con A supernatant and eluate, respectively; lanes 7 and 8, tunicamycin treated THV8.3 Con A supernatant and eluate, respectively.
- FIG. 4 Inhibition by soluble dextran of antibody binding to dextran coated ELISA plates. Percentage of antibody binding (ordinate) is plotted against dextran inhibitor concentration (abscissa). Plates were coated with 20 micrograms/ml dextran. Native antibodies and antibodies aglycosylated by tunicamycin treatment were used; trace quantities of glycosylated Ig present in tunicamycin treated TKC3.2 was removed by adsorption to Con A Sepharose.
- Apparent binding constants were determined using the method of Nieto et. al. (25).
- the association constant for an antibody is defined as the reciprocal free ligand concentration necessary for occupancy of one-half of the antibody binding sites. If a fixed amount of antibody Ab is reacted with increasing amounts of free ligand on a plate coated with solid-phase antigen, the reciprocal of the free ligand concentration which causes 50% inhibition of binding to the plate is a function of the intrinsic Ka, i.e., the apparent affinity constant (aKa).
- FIG. 5 General scheme for two primer site-directed mutagenesis.
- the Sal I-Bam HI fragment containing the IgG constant region exon is cloned into the M13 phage M13mp19 at the polylinker site.
- the positive-strand DNA template of the recombinant phage is prepared by the standard polyethylene glycol method.
- Two primers are used to produce the mutation, one the M13 sequencing primer, the other a 5′ end-phosphorylated mutagenic primer with one nucleotide mismatched in the consensus glycosylation sequence. Both primers are annealed to the template at the same time. After primer extension and ligation, the mutant/wild-type-gapped heteroduplex is used to transform E. coli host JM109.
- the present invention concerns a method of altering the affinity of an antibody for the antigen to which it is directed which comprises introducing into the variable region of the antibody a carbohydrate recognition site or sites under conditions such that a carbohydrate binds to the site and thus attaches to the antibody.
- the term “antibody” includes all types of antibodies including both human, non-human antibodies, and chimeric antibodies, both monoclonal and polyclonal antibodies, and all antibody isotypes, including the major classes of humoral immunoglobulins in humans, IgG, IgM, IgA, IgD, and IgE.
- the antibody is a monoclonal antibody; in another, the antibody is a human antibody.
- the affinity of an antibody for the antigen to which it is directed may be measured using techniques well known in the art.
- the affinity or binding of an antibody may be measured, for purpose of illustration, as follows.
- the association constant for an antibody is defined as the reciprocal free ligand concentration necessary for occupancy of one-half of the antibody binding sites. If a fixed amount of antibody is reacted with increasing amounts of free ligand on a plate coated with solid-phase antigen, the reciprocal of the free ligand concentration which causes 50% inhibition of binding to the plate is a function of the intrinsic Ka, i.e., the apparent affinity constant (aKa). Calculation of the constant may be carried out by interpolation of the inhibition curve assuming linearity near the point of 50% binding.
- the carbohydrate recognition site includes any specific amino acid sequence in an antibody to which a carbohydrate will specifically attach to the antibody.
- the presently best known such carbohydrate recognition site that is useful in accordance with teachings of the present invention, is the amino acid sequence:
- X may be any amino acid and Thr/Ser indicates a threonine or a serine.
- a site or sites may be introduced into the variable region of the antibody using methods well known in the art to which this invention pertains. See, for example, “In Vitro Mutagenesis,” Recombinant DNA: A Short Course , J. D. Watson, et al. W. H. Freeman and Company, New York, 1983, chapter 8, pp. 106-116.
- a particularly useful form of in vitro mutagenesis also well-known to those skilled in the art, is site-directed mutagenesis, which is described in Recombinant DNA: A Short Course and is exemplified in the Experimental Details section which follows.
- the carbohydrate recognition site may be introduced into the antibody by modifying or mutating an amino acid sequence so that the desired Asn-X-Thr/Ser sequence is obtained. If the sequence has an asparagine, or a threonine or serine, then at the next position two amino acids removed, a corresponding threonine or serine; or an asparagine, may be introduced, respectively, in order to obtain the desired Asn-X-Thr/Ser sequence, so that the antibody will then bind carbohydrate to the antibody.
- the carbohydrate recognition site may be introduced anywhere in the variable region of the antibody, this is provided only that its introduction does not destroy the ability of the antibody to bind antigen.
- the carbohydrate recognition site be introduced into that portion of the variable region known as the second hypervariable region or complementarity-determining region (CDR2).
- this invention provides a method of altering the affinity of an antibody for the antigen to which it is directed by introducing a carbohydrate recognition site into the second hypervariable region of the antibody.
- this invention provides a method for altering the affinity of an antibody.
- a carbohydrate recognition site is introduced into a variable region of an antibody which does not normally include a carbohydrate recognition site.
- the carbohydrate recognition site may be introduced into the variable region of the antibody by site-directed mutagenesis of DNA encoding the variable region of the antibody.
- This invention also provides a method of producing an antibody which may be more readily recovered or purified which comprises introducing into the variable region of the antibody a carbohydrate recognition site under conditions such that a carbohydrate binds to the site and thus attaches to the antibody, for example, a mouse or human monoclonal or polyclonal antibody.
- the carbohydrate recognition site is preferably introduced into a variable region of the antibody which does not normally include a carbohydrate recognition site, particularly the second hypervariable region of the antibody, using methods well known to those skilled in the art as are conditions for doing so under which carbohydrate attaches to the resulting antibody.
- the carbohydrate recognition site be introduced into the variable region of the antibody by site directed mutagenesis of DNA encoding the variable region of the antibody.
- This invention concerns an antibody, e.g., a mouse or human monoclonal or a human polyclonal antibody, which does not occur in nature and which comprises a carbohydrate recognition site genetically engineered into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region.
- the antibody is characterized by enhanced affinity for the antigen to which it is directed.
- the antibody may additionally comprise a carbohydrate attached to the carbohydrate recognition site which has been introduced or genetically engineered into the variable region of the antibody, e.g., into the second hypervariable region of the antibody.
- This invention also concerns an antibody in accordance with this invention labelled with a detectable marker.
- the antibody may have a detectable marker attached to, or incorporated into, one or more of the amino acids or carbohydrate which comprise its structure.
- a detectable marker may be any molecule or reagent which is capable of being detected, such as a chromophore, a fluorophore or a radioactive moiety, e.g., 125 I.
- the detectable marker may be an enzyme which catalyzes a reaction producing a detectable product, a chemiluminescent catalyst, biotin or a metal ion detectable by nuclear magnetic resonance.
- Suitable detectable markers include ligands capable of binding to specific proteins which have been tagged with an enzyme, e.g., horseradish peroxidase.
- an enzyme e.g., horseradish peroxidase.
- a suitable ligand is biotin, which will bind to avidin or streptavidin.
- Another suitable ligand is a hemin molecule, which will bind to the apoenzyme portion of catalase.
- this invention provides a solid support to which an antibody according to the invention is bound.
- the solid support may be in the form of a column for chromatographic separations or may be a bed or plate or the like for diagnostic application.
- the solid support may comprise, for example, silicaceous, cellulosic, plastic material, controlled pore glass, sepharose, cyanogen bromide- or DBM activated-paper, or nitrocellulose.
- this invention provides an altered antibody prepared by the method described herein in which the affinity of the antibody for the antigen to which it is directed is altered by introducing into the variable region of the antibody a carbohydrate recognition site or sites under conditions such that a carbohydrate binds to the site and thus attaches to the antibody.
- the present invention further contemplates deoxyribonucleic acid, DNA, encoding such an antibody. Methods to determine and produce DNA that encode specific antibodies, i.e., specific amino acid sequences, are well known in the art.
- This invention still further provides a method of modifying the carbohydrate content of an antibody, e.g., a mouse or human monoclonal or human polyclonal antibody, which comprises deleting from a constant region of the antibody a carbohydrate recognition site or sites which naturally occur in such constant region of such antibody.
- an antibody e.g., a mouse or human monoclonal or human polyclonal antibody
- deleting from a constant region of the antibody a carbohydrate recognition site or sites which naturally occur in such constant region of such antibody.
- a carbohydrate recognition site useful in accordance with this invention has the amino acid sequence
- X may be any amino acid and Thr/Ser indicates a threonine or serine.
- Deletion of such a site may be effected, by methods well known to those skilled in the art, for example, by site-directed mutagenesis of DNA encoding such constant region of the antibody, in which an asparagine, or a threonine or serine is replaced by another amino acid leading to deletion of the carbohydrate recognition site and thus preventing attachment of carbohydrate to the antibody.
- This invention provides a method of modifying the carbohydrate content of an antibody which comprises adding to a constant region of the antibody a carbohydrate recognition site or sites which does not naturally occur in such constant region of such antibody.
- This invention also provides a modified antibody so prepared. Once again, addition of the carbohydrate recognition site to the antibody may be effected by site-directed mutagenesis of DNA encoding such constant region of the antibody.
- the present invention additionally provides a method of modifying the biological effector function of an antibody which comprises modifying the carbohydrate content of the antibody using the method described hereinabove in which the carbohydrate content of the antibody is modified by deleting from a constant region of the antibody a carbohydrate recognition site or sites which naturally occur in such constant region of such antibody.
- Biological effector functions of antibodies which may be so modified include such functions as the ability to bind F c receptor and the ability to activate complement.
- a carbohydrate recognition site is to be introduced into, or deleted from a specifec region of the antibody, e.g., variable or constant region
- the altered or genetically engineered DNA is used to construct a complete antibody gene.
- the gene i.e., DNA sequence
- the gene is introduced into an expression vector and subsequently expressed in an appropriate cellular environment.
- a eukaryotic cell is preferred.
- a eu- or prokaryotic cell may be used.
- This invention also concerns a human antibody, e.g., a human monoclonal antibody, which does not occur in nature and which is characterized by the absence of a carbohydrate recognition site in a constant region of the antibody which naturally includes such carbohydrate recognition site is such constant region.
- the invention further provides DNA encoding such antibody.
- This invention also concerns a human antibody, e.g., a human monoclonal antibody, which does not occur in nature and which is characterized by the presence of a carbohydrate recognition site in a constant region of the antibody which does not naturally include such carbohydrate recognition site in such constant region.
- the invention further provides DNA encoding such antibody.
- the human antibody e.g., human monoclonal antibody
- a therapeutic ligand such as an anticancer drug such as ricin A chain, radionuclides, e.g., 125 I, or other therapeutant is bound to such carbohydrate attached to such antibody.
- therapeutic agents may be used for example to treat immune system abnormalities or other disease states.
- this human antibody is labelled, i.e., a label such as a detectable marker is bound to such carbohydrate attached to the antibody.
- This invention contemplates a modified antibody prepared by the method described herein in which the carbohydrate content of an antibody is modified by deleting from a constant region of the antibody a carbohydrate recognition site which naturally occurs in such constant region of such antibody as well as DNA encoding such an antibody.
- This invention also provides a more sensitive method for detecting the presence of a substance or analyte in a sample, such a human biological fluid sample, which comprises contacting the sample with an antibody directed to the substance.
- the antibody may be labelled with a detectable marker, e.g., a chromophore, a fluorophore or a radioactive moiety.
- a detectable marker e.g., a chromophore, a fluorophore or a radioactive moiety.
- Such an antibody as described hereinabove is one which does not occur in nature and which comprises a carbohydrate recognition site genetically enginerred into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region.
- the contacting is performed under conditions such that any substance or analyte present in the sample forms a detectable complex with the antibody and then detecting the presence of such complex and thus the presence of the substance.
- the antibody so employed is bound to a solid support of the type described hereinabove.
- the amount or concentration of the substance or analyte in the sample may also be qualified by determining the amount of complex formed, and thereby the amount or concentration of the substance or analyte, for example by comparison with a known amount of the substance or analyte.
- the quantitative determination of the amount or of complex formed by the substance and of the antibody directed to substance in a sample may be accomplished using methods which depend upon the identity of the detectable moiety but which are nevertheless in the well known art. Thus, if the detectable moiety is radioactive, a liquid scintillation counter may be employed. If the moiety is an enzyme, such as horseradish peroxidase in a standard assay, a spectrophotomer may be employed. If the moiety is flourescent, a flourometer may be used. One particularly useful approach involves flourescence activated cell sorting by means of which the method may be conveniently, rapidly and accurately carried out.
- This invention still further provides a method of recovering a substance from a sample containing the substance which comprises contacting the sample with antibody directed to the substance.
- the antibody has been described hereinabove as one which does not occur in nature and which comprises a carbohydrate recognition site genetically engineered into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region.
- Contacting is effected appropriate conditions such that substance in the sample forms a complex with the antibody.
- the substance is then recovered from the resulting complex.
- such a method is a chromatographic one in which the antibody is bound to a solid support packed into a column.
- This invention also contemplates a purification method for a substance which comprises recovering the substance from a sample containing the substance using the method, just described above, from a sample under conditions such that the substance is recovered in purified form.
- This invention yet further concerns a diagnostic kit comprising the antibody, described above, which does not occur in nature and which comprises a carbohydrate recognition site genetically engineered into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region. Additionally, this invention provides a diagnostic kit comprising such an antibody labelled with a detectable marker, such as a chromophore, fluorophore or radioactive moiety.
- a detectable marker such as a chromophore, fluorophore or radioactive moiety.
- assays that are useful in the methods provided by the present invention are well known to those skilled in the art pertaining to this invention.
- assays include liquid-phase assays, such as radioimmunoassays, and solid-phase assays, such as ELISA (Enzyme Linked Immunosorbent Assays) and the sandwich or IRMA (Immuno Radio-Metric Assay) assay.
- ELISA Enzyme Linked Immunosorbent Assays
- IRMA Immuno Radio-Metric Assay
- a particularly useful immunometric assay is the “two-site” or “sandwich” immunometric assay technique disclosed by David, et al., U.S. Pat. No. 4,376,110, the contents of which are hereby incorporated by reference.
- Assay conditions such as time of assay, pH, temperature, ionic strength of the assay, are also known to those skilled in the art.
- a general description of such widely known assays and conditions are described in Laboratory Techniques in Biochemistry and Molecular Biology , vol. 13 , Monoclonal Antibody Technology , A. M. Campbell, Elsevier, N.Y., 1986, chapter 2, “Assay Techniques,” pp. 33-65.
- V H regions from the three hybridoma antibodies to alpha (1 ⁇ 6) dextran were joined to the human IgG 4 constant region gene (FIG. 1) and after transfection of D3, a cell line producing only the hybridoma specific light chain (4,5), directed the expression of an H chain which assembled with the endogenous light chain and was secreted (results not shown).
- the nucleotide sequence of the variable regions of the heavy chain (V H ) and of the light chain (V L ) were determined (2) (Table I).
- tunicamycin is a potent inhibitor of N-linked glycosylation (8), it is difficult to produce proteins completely free of glycosylated species. From reconstruction experiments it was apparent that even a trace contamination of high affinity antibody could dramatically increase the apparent binding constant for dextran of the low affinity antibody (data not shown). To avoid this Con A was used which binds high mannose and biantennary complex oligosaccharides (9) to separate unglycosylated from glycosylated immunoglobulin.
- TKC3.2 and THV8.3 antibodies resulted in an electrophoretic mobility change consistent with the loss of carbohydrate from the H chain (FIG. 3B, lanes 1-4).
- H chains which contain two, one and zero-N linked carbohydrate moieties (lanes 1, 3 and 2 or 4, respectively) can be resolved.
- the H chain bands of the untreated samples (lanes 1 and 3) appear homogeneous suggesting all H chains are uniformly glycosylated. From the lack of visible glycosylated H chain bands in lanes 2, 4 and 6 it was estimated that tunicamycin treatment results in greater than 97% deglycosylation of the immunoglobulin.
- Lanes 5-8 show the results obtained from Con A adsorption of tunicamycin treated immunoglobulin. Both the TKC3.2 (V H 14.6b.1) and THV8.3 (V H 19.22.1) aglycosylated antibodies were not bound by Con A (lanes 5 and 7).
- the aglycosylated TKC3.2 (V H 14.6b.1) antibodies, and native THV8.3 antibody showed 50% maximal binding when 18-24 micrograms/ml dextran B512 inhibitor was added.
- glycohydrolase Endo H was used to investigate the structure of the V H oligosaccharide.
- the di-N-acetylchitobiose linkage of high mannose core oligosaccharides found on newly synthesized IgG H chains is susceptible to Endo H cleavage (11), while processed complex carbohydrates are resistant to Endo H cleavage.
- H chains obtained from cell cytoplasms were hydrolyzed by Endo H (data not shown).
- heavy chains from the secretions of both THV8.3 and TKC3.2 were unaltered by Endo H treatment.
- Antibodies are glycoproteins with all heavy chains containing at least one and frequently several N-linked carbyhydrate residues (12).
- the role postulated for carbohydrate found on the heavy chain constant regions includes solubilization of the H chain, facilitation of subcellular transport and secretion, promotion of assembly, and maintenance of immunoglobulin conformational features which contribute to effector functions (13).
- Carbohydrate can also be found within the V region of an antibody molecule. Fifteen percent of human myeloma light chains have carbohydrate within their variable regions. (14). In a study of 76 human IgG myeloma proteins, approximately 25% were shown to contain a carbohydrate moiety on the Fab fragment (15). The carbohydrate was linked to either the light chains or the Fd fragments, and in a few cases to both.
- FIG. 5 Many different approaches exist for site-directed mutagenesis; one approach used in the present invention is illustrated in FIG. 5 (24).
- the Sal I-Bam HI fragment containing the IgG constant region exon is cloned into the M13 phage M13mp19 at the polylinker site.
- the positive-strand DNA template of the recombinant phage is prepared by the standard polyethylene glycol method.
- Two primers are used to produce the mutation, one the M13 sequencing primer, the other a 5′ end-phosphorylated mutagenic primer with one nucleotide mismatched in the consensus glycosylation sequence. Both primers are annealed to the template at the same time.
- the mutant/wild-type-gapped heteroduplex is used to transform E. coli host JM109.
- colony hybridization is employed. Under low stringency hybridization conditions, both the mutant and the wild type phage hybridize with the mutagenic oligomer.
- stringency of the hybridization conditions is increased, e.g., by increasing the temperature at which the hybridized phage plaques are washed, the labeled mutagenic oligomer remains hybridized with the mutant phage DNA but dissociates from the nonmutant phage DNA.
- the exact nucleotide change introduced into the immunoglobulin heavy chain must be confirmed by sequencing the DNA; the dideoxy method of sequencing is used (25, 26).
- the mutagenized gene is then transferred into an expression vector, where it can be used to direct the synthesis of an altered protein. This general approach can be used to introduce changes anywhere within the antibody molecule and may have particular application to the production of antibody molecules with altered idiotypes.
- This approach could also be used to put additional carbohydrate molecules in the constant region. This could be useful when ligands are attached to antibodies via their carbohydrate.
Abstract
Description
- [0001] The invention described herein was made, in part, in the course of work under Grant Numbers AI 19042, CA 16858, CA 22736 and CA 13696 from the National Institute for Health, U.S. Department of Health and Human Services. The U.S. Government has certain rights in this invention.
- Throughout this application, various publications are referenced by Arabic numerals. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.
- Immunochemical characterization of antibodies to alpha (1→6) dextran has given insights into the size and shape of the antibody combining site and the nature of the interaction between antibodies and antigen. In this regard, it would be useful to correlate the immunochemical properties of the anti-dextran antibodies with their primary structure. In the course of these studies, cDNAs from three monoclonal anti-alpha (1→6) dextran hybridoma cell lines, 14.6b.1, 5.54.4.24.1, and 19.22.1, were cloned (1) and the nucleotide sequences of the variable regions of the heavy chain (VH) and of the light chain (VL) determined (2) (see Table I on page 22 of this application). All synthesize an identical kappa light chain with the Vkappa-OX1 germline gene (3) rearranged to the
J kappa2 segment and the heavy chains differ by only one or two amino acids in their complementarity-determining regions (CDRs). When compared to 14.6b.1, 5.54.4.24.1 and 19.22.1 have an identical Thr→Asn amino acid change at position 60 in the variable region of the heavy chain (VH); 5.54.4.24.1 has an additional change (Ser→Gly) at position 31 in complementarity-determining region 1 (CDR1). The changes in heavy chain sequence result in 5.54.4.24.1 and 19.22.1 having a (ten) 10 fold or greater reduction in their binding constant for both polymeric dextran and isomaltoheptaose (IM7) when compared to 14.6b.1 (Table I). - The Thr→Asn change in 5.54.4.24 and 19.22.1 leads to the loss of a potential N-linked glycosylation site (Asn 58-Tyr 59-Thr 60) present in 14.6b.1. One of the purposes of this study and the present invention was to determine whether this potential N-linked glycosylation site is glycosylated, and if so, whether the addition of carbohydrate to complementarity-determining region 2 (CDR2) affects the binding constant for dextran. It is difficult to demonstrate glycosylation of VH directly since both Immunoglobulin A (IgA) and Immunoglobulin M (IgM) isotypes are glycosylated within their
C H1 domains and carbohydrate present in Fd could be linked to either VH or constant region of the heavy chain (CH). Fd is the product resulting from the chemical or enzymatic cleavage of the antibody and comprises the heavy chain of the variable region and the heavy chain of the constant region of the antibody. Therefore, the three VH regions have been transferred to the human IgG4 constant region which is devoid of carbohydrate in itsC H1 domain. In this invention, the presence of carbohydrate is demonstrated to be within the VH of 14.6b.1. Comparison of the association constants for aglycosylated, tunicamycin treated and untreated antibodies shows that the presence of carbohydrate increases the apparent association constant (aKa) of 14.6b.1 for dextran. The effect on binding is unique to the carbohydrate present in VH since absence of carbohydrate fromC H2 does not change the aKa for dextran. - By introducing into an antibody a carbohydrate recognition site for the attachment of carbohydrate, purification of the antibody can be enhanced because the carbohydrate is attached to the outside of the antibody and thus, is more accessible to binding by lectin (purification).
- In this invention, the carbohydrate content of an antibody may be modified by adding or deleting carbohydrate recognition sites in the constant region of the antibody. In so doing, effector functions of the antibody are modified. Carbohydrate recognition sites in the constant region can also serve as sites for labelling, e.g., radionuclides, such as125I.
- This invention concerns a method of altering the affinity of an antibody for the antigen to which it is directed which comprises introducing into the variable region of the antibody a carbohydrate recognition site under conditions such that a carbohydrate binds to the site and thus attaches to the antibody.
- This invention also concerns a method of producing an antibody which may be more readily recovered or purified which comprises introducing into the variable region of the antibody a carbohydrate recognition site under conditions such that a carbohydrate binds to the site and thus attaches to the antibody.
- This invention further provides an antibody which does not occur in nature and which comprises a carbohydrate recognition site genetically engineered into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region.
- Still further, the present invention provides a method of modifying the carbohydrate content of an antibody which comprises deleting from a constant region of the antibody a carbohydrate recognition site which naturally occurs in such constant region of such antibody.
- The invention also provides a method of modifying the carbohydrate content of an antibody which comprises adding to a constant region of the antibody a carbohydrate recognition site which does not naturally occur in such constant region of such antibody.
- This invention further concerns a human antibody which does not occur in nature and which is characterized by the absence of a carbohydrate recognition site in a constant region of the antibody which naturally includes such a carbohydrate recognition site in such constant region.
- Further, this invention provides a human antibody which does not occur in nature and which is characterized by the presence of a carbohydrate recognition site in a constant region of the antibody which does not naturally include such a carbohydrate recognition site in such constant region.
- Finally, this invention provides therapeutic agents derived from, and DNA encoding, the antibodies, of the invention as well as sensitive methods for detecting the presence of substances in a sample, methods for recovering a substance from a sample containing the substance and for purifying such substance, and diagnostic test kits.
- FIG. 1. Substitution of the genomic VH region with VH cDNA and isotype switch. A genomic EcoRI fragment containing the MPC11 H chain promoter, leader sequence, rearranged V region, and Ig enhancer (22) was cloned into the EcoRI site of a pBR322 derivative deleted of nucleotide 2065 through 29. Using cDNA produced from the anti-alpha (1→6) dextran hybridomas (2), the V region of MPC11 was replaced by the anti-dextran V region by inserting the PvuII-PstI cDNA fragment into PvuII-PstI cleaved MPC11. The first four VH amino acids are derived from MPC11, but are identical to those found in the three cDNAs (22). The EcoRI fragment containing the dextran VH was joined to a human IgG4 constant region within the pSV2-gpt expression vector (23, 4). The coding sequences of the MPC11 and cDNA genes are shown as solid and hatched lines, respectively. The dotted boxes represent the coding sequences of the human IgG4 constant region. The maps are not drawn to scale.
- FIG. 2. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of immunoprecipitates obtained after papain digestion of A) [35S]-Met or B) [14C]-glucosamine labelled secreted Ig. Secretions of cells labelled in the presence of 15 micro Ci/ml of [35S]-Met or 100 micro Ci/mi [14C]-D-glucosamine hydrochloride (24) were digested with papain (Sigma Chemical Co., St. Louis, Mo.) at 1:100 enzyme:protein ratio for four hours at 37° C. The reaction was stopped by addition of iodoacetamide to 0.03 M. The Fc fraction and undigested antibody protein were precipitated by incubation with IgG Sorb (Enzyme Center, Malden, Mass.). Antigen binding fragment (Fab) was precipitated from the supernatant using rabbit anti-human Fab or by insolubilized dextran (Sephadex® G75). Samples were reduced with beta-mercaptoethanol. (0.15 M) and analyzed using 5% SDS-PAGE (16). The heavy chains produced by the transfectant cell lines are as follows: THV8, VH 19.22.1; TJC8.5, VH 5.54.4.24.1; TKC3.2, VH 14.6b.1; all transfectants synthesize the alpha (1→6) dextran specific light chain. [35S]-Met labelled and reduced Igs were used as markers. In FIG. 2A the TKC3.2 (Fab) and TKC3.2 samples were analyzed on a separate SDS-PAGE gel.
- FIG. 3. 12.5% Tris-glycine SDS-PAGE analysis of [35S]-Met labelled transfectoma culture supernatants, immunoprecipitated with rabbit anti-human Ig fragment constant region (Fc) antiserum following Concanavalin A (Con A) adsorption (as indicated) and/or tunicamycin treatment. Tunicamycin at a concentration of 8 micrograms/ml (Boehringer Mannheim, West Germany) was used to inhibit N-Linked glycosylation. Cells were biosynthetically labelled for three hours with [35S]-Met in the presence of tunicamycin, the secreted Ig in the culture supernatant discarded, the cells washed with Ipco Modified Dulbecco's Medium (IMDM) medium twice; fresh tunicamycin and [35S]-Met was added; and treatment continued overnight at 37° C. Samples were reduced with 0.15 M beta-mercaptoethanol prior to SDS-PAGE. The positions of the H and L chains are indicated.
- 3A. Con A—sepharose adsorption of secreted transfectoma Ig.
Lanes Lanes lanes - 3B. Tunicamycin treated cell supernatants without or with Con A—Sepharose adsorption.
Lanes lanes lanes - FIG. 4. Inhibition by soluble dextran of antibody binding to dextran coated ELISA plates. Percentage of antibody binding (ordinate) is plotted against dextran inhibitor concentration (abscissa). Plates were coated with 20 micrograms/ml dextran. Native antibodies and antibodies aglycosylated by tunicamycin treatment were used; trace quantities of glycosylated Ig present in tunicamycin treated TKC3.2 was removed by adsorption to Con A Sepharose.
- Apparent binding constants were determined using the method of Nieto et. al. (25). In brief, the association constant for an antibody is defined as the reciprocal free ligand concentration necessary for occupancy of one-half of the antibody binding sites. If a fixed amount of antibody Ab is reacted with increasing amounts of free ligand on a plate coated with solid-phase antigen, the reciprocal of the free ligand concentration which causes 50% inhibition of binding to the plate is a function of the intrinsic Ka, i.e., the apparent affinity constant (aKa).
- Calculation for the constant is carried out by interpolation of the inhibition curve assuming linearity near the point of 50% binding. The following experimental conditions have been employed to measure the aKa values. Corning microtiter plates were coated with 0.5 micrograms/ml or 20 micrograms/ml dextran B512 (high affinity and low affinity assay conditions, respectively). Bound immunoglobulin Ig was quantitated using anti-human IgG labelled with horseradish peroxidase.
- FIG. 5. General scheme for two primer site-directed mutagenesis. The Sal I-Bam HI fragment containing the IgG constant region exon is cloned into the M13 phage M13mp19 at the polylinker site. The positive-strand DNA template of the recombinant phage is prepared by the standard polyethylene glycol method. Two primers are used to produce the mutation, one the M13 sequencing primer, the other a 5′ end-phosphorylated mutagenic primer with one nucleotide mismatched in the consensus glycosylation sequence. Both primers are annealed to the template at the same time. After primer extension and ligation, the mutant/wild-type-gapped heteroduplex is used to transformE. coli host JM109.
- The present invention concerns a method of altering the affinity of an antibody for the antigen to which it is directed which comprises introducing into the variable region of the antibody a carbohydrate recognition site or sites under conditions such that a carbohydrate binds to the site and thus attaches to the antibody.
- As used in the context of this invention, the term “antibody” includes all types of antibodies including both human, non-human antibodies, and chimeric antibodies, both monoclonal and polyclonal antibodies, and all antibody isotypes, including the major classes of humoral immunoglobulins in humans, IgG, IgM, IgA, IgD, and IgE. In one embodiment of this invention, the antibody is a monoclonal antibody; in another, the antibody is a human antibody.
- The affinity of an antibody for the antigen to which it is directed may be measured using techniques well known in the art. The affinity or binding of an antibody may be measured, for purpose of illustration, as follows. The association constant for an antibody is defined as the reciprocal free ligand concentration necessary for occupancy of one-half of the antibody binding sites. If a fixed amount of antibody is reacted with increasing amounts of free ligand on a plate coated with solid-phase antigen, the reciprocal of the free ligand concentration which causes 50% inhibition of binding to the plate is a function of the intrinsic Ka, i.e., the apparent affinity constant (aKa). Calculation of the constant may be carried out by interpolation of the inhibition curve assuming linearity near the point of 50% binding.
- As used herein, the carbohydrate recognition site includes any specific amino acid sequence in an antibody to which a carbohydrate will specifically attach to the antibody. The presently best known such carbohydrate recognition site that is useful in accordance with teachings of the present invention, is the amino acid sequence:
- Asn-X-Thr/Ser
- wherein X may be any amino acid and Thr/Ser indicates a threonine or a serine. Such a site or sites may be introduced into the variable region of the antibody using methods well known in the art to which this invention pertains. See, for example, “In Vitro Mutagenesis,”Recombinant DNA: A Short Course, J. D. Watson, et al. W. H. Freeman and Company, New York, 1983, chapter 8, pp. 106-116. A particularly useful form of in vitro mutagenesis, also well-known to those skilled in the art, is site-directed mutagenesis, which is described in Recombinant DNA: A Short Course and is exemplified in the Experimental Details section which follows.
- Thus, the carbohydrate recognition site may be introduced into the antibody by modifying or mutating an amino acid sequence so that the desired Asn-X-Thr/Ser sequence is obtained. If the sequence has an asparagine, or a threonine or serine, then at the next position two amino acids removed, a corresponding threonine or serine; or an asparagine, may be introduced, respectively, in order to obtain the desired Asn-X-Thr/Ser sequence, so that the antibody will then bind carbohydrate to the antibody.
- Although the carbohydrate recognition site may be introduced anywhere in the variable region of the antibody, this is provided only that its introduction does not destroy the ability of the antibody to bind antigen. Presently, it is preferred that the carbohydrate recognition site be introduced into that portion of the variable region known as the second hypervariable region or complementarity-determining region (CDR2). Thus, this invention provides a method of altering the affinity of an antibody for the antigen to which it is directed by introducing a carbohydrate recognition site into the second hypervariable region of the antibody. In another embodiment this invention provides a method for altering the affinity of an antibody. In this method, a carbohydrate recognition site is introduced into a variable region of an antibody which does not normally include a carbohydrate recognition site. Numerous methods exist for introducing the carbohydrate recognition site into the antibody and are well known to those skilled in the art to which this invention relates. For example, the carbohydrate recognition site may be introduced into the variable region of the antibody by site-directed mutagenesis of DNA encoding the variable region of the antibody.
- This invention also provides a method of producing an antibody which may be more readily recovered or purified which comprises introducing into the variable region of the antibody a carbohydrate recognition site under conditions such that a carbohydrate binds to the site and thus attaches to the antibody, for example, a mouse or human monoclonal or polyclonal antibody. Once again the carbohydrate recognition site is preferably introduced into a variable region of the antibody which does not normally include a carbohydrate recognition site, particularly the second hypervariable region of the antibody, using methods well known to those skilled in the art as are conditions for doing so under which carbohydrate attaches to the resulting antibody. In this embodiment of the invention it is also presently preferred that the carbohydrate recognition site be introduced into the variable region of the antibody by site directed mutagenesis of DNA encoding the variable region of the antibody.
- Those skilled in the art will readily appreciate that one of the limitations associated with the use of antibodies, particularly monoclonal antibodies, is the ability to recover the antibodies in high yield and at high levels of purity without denaturing the antibody. The ability to introduce a carbohydrate onto the exposed variable region of an antibody will greatly facilitate such recovery, for example, by permitting the use of adsorption chromatography onto a lectin.
- This invention concerns an antibody, e.g., a mouse or human monoclonal or a human polyclonal antibody, which does not occur in nature and which comprises a carbohydrate recognition site genetically engineered into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region. In one embodiment, the antibody is characterized by enhanced affinity for the antigen to which it is directed. The antibody may additionally comprise a carbohydrate attached to the carbohydrate recognition site which has been introduced or genetically engineered into the variable region of the antibody, e.g., into the second hypervariable region of the antibody.
- This invention also concerns an antibody in accordance with this invention labelled with a detectable marker. For example, the antibody may have a detectable marker attached to, or incorporated into, one or more of the amino acids or carbohydrate which comprise its structure. Such a marker may be any molecule or reagent which is capable of being detected, such as a chromophore, a fluorophore or a radioactive moiety, e.g.,125I. Additionally, the detectable marker may be an enzyme which catalyzes a reaction producing a detectable product, a chemiluminescent catalyst, biotin or a metal ion detectable by nuclear magnetic resonance. Other suitable detectable markers include ligands capable of binding to specific proteins which have been tagged with an enzyme, e.g., horseradish peroxidase. One example of a suitable ligand is biotin, which will bind to avidin or streptavidin. Another suitable ligand is a hemin molecule, which will bind to the apoenzyme portion of catalase. Those skilled in the art will be readily familiar with methods for attaching or introducing such detectable markers onto antibodies and for using antibodies which are so labelled.
- In still another embodiment, this invention provides a solid support to which an antibody according to the invention is bound. The solid support may be in the form of a column for chromatographic separations or may be a bed or plate or the like for diagnostic application. The solid support may comprise, for example, silicaceous, cellulosic, plastic material, controlled pore glass, sepharose, cyanogen bromide- or DBM activated-paper, or nitrocellulose.
- In another aspect, this invention provides an altered antibody prepared by the method described herein in which the affinity of the antibody for the antigen to which it is directed is altered by introducing into the variable region of the antibody a carbohydrate recognition site or sites under conditions such that a carbohydrate binds to the site and thus attaches to the antibody. The present invention further contemplates deoxyribonucleic acid, DNA, encoding such an antibody. Methods to determine and produce DNA that encode specific antibodies, i.e., specific amino acid sequences, are well known in the art.
- This invention still further provides a method of modifying the carbohydrate content of an antibody, e.g., a mouse or human monoclonal or human polyclonal antibody, which comprises deleting from a constant region of the antibody a carbohydrate recognition site or sites which naturally occur in such constant region of such antibody. As described hereinabove, a carbohydrate recognition site useful in accordance with this invention has the amino acid sequence
- Asn-X-Thr/Ser
- wherein X may be any amino acid and Thr/Ser indicates a threonine or serine.
- Deletion of such a site may be effected, by methods well known to those skilled in the art, for example, by site-directed mutagenesis of DNA encoding such constant region of the antibody, in which an asparagine, or a threonine or serine is replaced by another amino acid leading to deletion of the carbohydrate recognition site and thus preventing attachment of carbohydrate to the antibody.
- This invention provides a method of modifying the carbohydrate content of an antibody which comprises adding to a constant region of the antibody a carbohydrate recognition site or sites which does not naturally occur in such constant region of such antibody. This invention also provides a modified antibody so prepared. Once again, addition of the carbohydrate recognition site to the antibody may be effected by site-directed mutagenesis of DNA encoding such constant region of the antibody.
- The present invention additionally provides a method of modifying the biological effector function of an antibody which comprises modifying the carbohydrate content of the antibody using the method described hereinabove in which the carbohydrate content of the antibody is modified by deleting from a constant region of the antibody a carbohydrate recognition site or sites which naturally occur in such constant region of such antibody. Biological effector functions of antibodies which may be so modified include such functions as the ability to bind Fc receptor and the ability to activate complement.
- Where, according to this invention, a carbohydrate recognition site is to be introduced into, or deleted from a specifec region of the antibody, e.g., variable or constant region, the altered or genetically engineered DNA is used to construct a complete antibody gene. In turn, the gene, i.e., DNA sequence, is introduced into an expression vector and subsequently expressed in an appropriate cellular environment. For antibody molecules containing carbohydrate, a eukaryotic cell is preferred. For antibody molecules lacking carbohydrate, a eu- or prokaryotic cell may be used. Those skilled in the art to which this invention relates will readily appreciate the well known techniques, by which such DNA sequences or genes are constructed, the manner of introduction into expression vectors, the types of vectors which are useful, and conditions and manner of expression in an appropriate cellular environment.
- This invention also concerns a human antibody, e.g., a human monoclonal antibody, which does not occur in nature and which is characterized by the absence of a carbohydrate recognition site in a constant region of the antibody which naturally includes such carbohydrate recognition site is such constant region. The invention further provides DNA encoding such antibody.
- This invention also concerns a human antibody, e.g., a human monoclonal antibody, which does not occur in nature and which is characterized by the presence of a carbohydrate recognition site in a constant region of the antibody which does not naturally include such carbohydrate recognition site in such constant region. The invention further provides DNA encoding such antibody.
- The human antibody, e.g., human monoclonal antibody, may have a carbohydrate attached to such carbohydrate recognition site and in one embodiment of this invention, may be employed as a therapeutic agent when a therapeutic ligand such as an anticancer drug such as ricin A chain, radionuclides, e.g.,125I, or other therapeutant is bound to such carbohydrate attached to such antibody. Such therapeutic agents may be used for example to treat immune system abnormalities or other disease states. Still in other embodiments, this human antibody is labelled, i.e., a label such as a detectable marker is bound to such carbohydrate attached to the antibody.
- This invention contemplates a modified antibody prepared by the method described herein in which the carbohydrate content of an antibody is modified by deleting from a constant region of the antibody a carbohydrate recognition site which naturally occurs in such constant region of such antibody as well as DNA encoding such an antibody.
- This invention also provides a more sensitive method for detecting the presence of a substance or analyte in a sample, such a human biological fluid sample, which comprises contacting the sample with an antibody directed to the substance. The antibody may be labelled with a detectable marker, e.g., a chromophore, a fluorophore or a radioactive moiety. Such an antibody as described hereinabove is one which does not occur in nature and which comprises a carbohydrate recognition site genetically enginerred into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region. In this method the contacting is performed under conditions such that any substance or analyte present in the sample forms a detectable complex with the antibody and then detecting the presence of such complex and thus the presence of the substance. In one embodiment the antibody so employed is bound to a solid support of the type described hereinabove.
- The amount or concentration of the substance or analyte in the sample may also be qualified by determining the amount of complex formed, and thereby the amount or concentration of the substance or analyte, for example by comparison with a known amount of the substance or analyte. The quantitative determination of the amount or of complex formed by the substance and of the antibody directed to substance in a sample may be accomplished using methods which depend upon the identity of the detectable moiety but which are nevertheless in the well known art. Thus, if the detectable moiety is radioactive, a liquid scintillation counter may be employed. If the moiety is an enzyme, such as horseradish peroxidase in a standard assay, a spectrophotomer may be employed. If the moiety is flourescent, a flourometer may be used. One particularly useful approach involves flourescence activated cell sorting by means of which the method may be conveniently, rapidly and accurately carried out.
- This invention still further provides a method of recovering a substance from a sample containing the substance which comprises contacting the sample with antibody directed to the substance. The antibody has been described hereinabove as one which does not occur in nature and which comprises a carbohydrate recognition site genetically engineered into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region. Contacting is effected appropriate conditions such that substance in the sample forms a complex with the antibody. The substance is then recovered from the resulting complex. In a further aspect, such a method is a chromatographic one in which the antibody is bound to a solid support packed into a column.
- This invention also contemplates a purification method for a substance which comprises recovering the substance from a sample containing the substance using the method, just described above, from a sample under conditions such that the substance is recovered in purified form.
- This invention yet further concerns a diagnostic kit comprising the antibody, described above, which does not occur in nature and which comprises a carbohydrate recognition site genetically engineered into a variable region of the antibody which does not naturally include a carbohydrate recognition site in such variable region. Additionally, this invention provides a diagnostic kit comprising such an antibody labelled with a detectable marker, such as a chromophore, fluorophore or radioactive moiety. The various method for detecting the presence of a substance in a sample and for recovering a substance from a sample containing the substance are based upon the novel antibodies of this invention and the substances forming a complex, and are described more fully herein.
- The types of assays that are useful in the methods provided by the present invention are well known to those skilled in the art pertaining to this invention. Among such assays are liquid-phase assays, such as radioimmunoassays, and solid-phase assays, such as ELISA (Enzyme Linked Immunosorbent Assays) and the sandwich or IRMA (Immuno Radio-Metric Assay) assay. With respect to the latter assay, a particularly useful immunometric assay is the “two-site” or “sandwich” immunometric assay technique disclosed by David, et al., U.S. Pat. No. 4,376,110, the contents of which are hereby incorporated by reference. Assay conditions such as time of assay, pH, temperature, ionic strength of the assay, are also known to those skilled in the art. A general description of such widely known assays and conditions are described inLaboratory Techniques in Biochemistry and Molecular Biology, vol. 13, Monoclonal Antibody Technology, A. M. Campbell, Elsevier, N.Y., 1986,
chapter 2, “Assay Techniques,” pp. 33-65. - This invention is illustrated in the Experimental Detail Discussion section which follow. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.
- Materials and Methods
- Cloning and Expression of Chimeric Heavy Chains With Variable Regions Derived From Anti-dextran Hybridomas
- The expressed VH regions from the three hybridoma antibodies to alpha (1→6) dextran were joined to the human IgG4 constant region gene (FIG. 1) and after transfection of D3, a cell line producing only the hybridoma specific light chain (4,5), directed the expression of an H chain which assembled with the endogenous light chain and was secreted (results not shown). The nucleotide sequence of the variable regions of the heavy chain (VH) and of the light chain (VL) were determined (2) (Table I).
TABLE I Immunochemical properties of Hybridoma Antibodies Specific for Dextran B512 Heavy Chains House amino acid changes Strain Site Ka (ml/g)d Kia (M−1)d,e v. 14.6b.1 prototypef Hybridoma Origin Isotype Sizec Dextran (IM7) CDR1 CDR2 CDR3J −H 14.6b.1a BALB/c IgA, k 6 4.43 × 105 5.76 × 104 — — −3 5.54.4.24.1b C57BL/6 IgA, k 6 1.78 × 104 3.02 × 103 31 Ser−>Gly 60 Thr−>Asn −3 19.22.1a BALB/c IgM,k 7 8.87 × 103 6.46 × 103 — 60 Thr−>Asn −3 - To determine if the 14.6b.1 chimeric antibody contained carbohydrate in VH the molecule was fractionated into Fab and Fc by papain cleavage, then the molecules were reduced with beta-mercaptoethanol, and analyzed on 5% SDS-PAGE gels. Proteins were labelled with [35S]-Met and the Fab precipitated using specific anti-Fab antiserum (FIG. 2A). Transfectoma antibodies with VH derived from 5.54.4.24.1 and 19.22.1 cDNA clones (TJC8 and THV8, respectively) show comigration of their Fd and kappa light chains. In contrast in transfectoma antibodies whose H chain variable region is from 14.6b.1 (TKC3.2) the Fd portion migrates more slowly than the L chain. The reduced mobility of the 14.6b.1 Fd fragment is consistent with glycosylation of its VH.
- To confirm the presence of carbohydrate in the VH of 14.6b.1, the secreted immunoglobulin was labelled with [14C]-glucosamine, Fab and Fc fractions were prepared and the products analyzed by SDS-PAGE (FIG. 2B). As anticipated the kappa light chains do not contain carbohydrate and bands are absent. [14C]-glucosamine labelling of the human IgG Fc fragment was found which contains N-linked carbohydrate within its
C H2 domain (6). However, only TKC3.2(Fab) with its Fd obtained from the 14.6b.1 VH shows glucosamine labelling. The reduced intensities of the Fd bands relative to the Fc is probably due to poor recovery of the Fab fragment rather than incomplete glycosylation (7). In SDS-PAGE gels in which H chains could be resolved containing no, one or two carbohydrate moieties (FIG. 3A), only one heavy chain band for TKC3.2 was found. - Role of the Carbohydrate in the Antigen-Antibody Interaction.
- To examine the role of carbohydrate in antigen binding, the association constants for tunicamycin treated aglycosylated and untreated native anti-dextran transfectoma antibodies were determined. Although tunicamycin is a potent inhibitor of N-linked glycosylation (8), it is difficult to produce proteins completely free of glycosylated species. From reconstruction experiments it was apparent that even a trace contamination of high affinity antibody could dramatically increase the apparent binding constant for dextran of the low affinity antibody (data not shown). To avoid this Con A was used which binds high mannose and biantennary complex oligosaccharides (9) to separate unglycosylated from glycosylated immunoglobulin. Adsorption experiments showed that the carbohydrate in THV8.3 antibody (VH 14.6b.1) was not absorbed to Con A sepharose (FIG. 3A,
lanes 2 and 4). The residual TKC3.2 antibody seen in the Con A supernatant (lane 2) may reflect the inability to separate the Con A slurry completely from the culture fluid. - Tunicamycin treatment of both TKC3.2 and THV8.3 antibodies resulted in an electrophoretic mobility change consistent with the loss of carbohydrate from the H chain (FIG. 3B, lanes 1-4). H chains which contain two, one and zero-N linked carbohydrate moieties (
lanes lanes 1 and 3) appear homogeneous suggesting all H chains are uniformly glycosylated. From the lack of visible glycosylated H chain bands inlanes lanes 5 and 7). - Having established that Con A adsorption could remove glycosylated contaminants from TKC3.2 tunicamycin treated preparations, Con A absorbed material was next used for dextran binding studies. The results from one typical experiment are graphically illustrated in FIG. 4. For the native TKC3.2 antibody (VH 14.6b.1) 50% inhibition of binding to ELISA plates coated with 0.5 micrograms/ml or 20 micrograms/ml dextran was obtained when 1.2 micrograms/ml of dextran inhibitor was added. Carbohydrate depleted TKC3.2 antibody (VH 14.6b.1) could not bind to 0.5 micrograms/ml dextran coated plates (data not shown). Using low affinity binding conditions (microtiter wells coated with 20 micrograms/ml dextran) the aglycosylated TKC3.2 (VH 14.6b.1) antibodies, and native THV8.3 antibody showed 50% maximal binding when 18-24 micrograms/ml dextran B512 inhibitor was added.
- The apparent association constants for tunicamycin treated aglycosylated and untreated native anti-dextran antibodies are summarized in Table II.
TABLE II Apparent Binding Constants for Dextran. B512. aKa (ml/g)a aKa (ml/g) Hybridoma or (Tabulated from Calculated from Transfectoma Ab FIG. 4) Several Experiments 14.6b.1 n.d.b 2.30 ± 0.1 × 106 (4)c (4.43 × 105)d 19.22.1 n.d n.d. (8.87 × 103)d TKC3.2 (−Tm) 1.7 × 106 1.68 ± 0.6 × 106 (8)e (2.10) ± 0.3 × 106)g (5) TKC3.2 (+Tm) Con A 1.1 × 105 1.18 ± 0.04 × 105 (5) adsorbed THV8.3 (−Tm) 1.0 × 105 8.22 ± 3.6 × 104 (10)f (6.5 ± 0.3 × 104)g (6) THV8.3 (+Tm) Con A 8.3 × 104 1.09 ± 0.4 × 105 (4) adsorbed - To determine antibody concentrations culture supernatants diluted into BBS (0.02M borate-buffered, 0.75% saline, pH 8.3) were bound to polystyrene microtiter wells (Corning, N.Y.) for three hours at 37° C. After blocking any unreacted sites with 1% bovine serum albumin/0.05
% Tween® 20 PBS (PBS.T.S) for one hour at room temperature, the Enzyme-linked immunosorbent assay (ELISA) plates were washed with PBS/0.5% Tween three times, PBS once, and then bound Ig was quantitated by reaction with horse-radish peroxidase labelled anti-human IgG antibody and comparison to a human IgG standard of known concentration. Assay results have been reproduced at least three times. - The binding constant of the carbohydrate depleted TKC3.2 antibody (VH 14.6b.1) was 14-15 fold lower than the native antibody. In contrast, carbohydrate removed from the Fc of THV8.3 (VH 19.22.1) did not affect the ability of the antibodies to bind antigen. All experiments except those noted were preformed using an antibody concentration of 1 microgram/ml. A slight effect of antibody concentration on apparent aKa values was observed. The aKa values determined using the inhibition ELISA were, in general 3-5 fold higher than those obtained by affinity gel electorphoresis but the differences in binding strength between antibodies were similar using the two assays. A 32-fold difference in binding affinity between the TKC3.2 (VH 14.6b.1) and THV8.3 (VH 19.22.1) antibodies was found, versus the 50-fold difference between 14.6b.1 and 19.22.1 reported previously (10). In summary it is clear that the presence of carbohydrate within the anti-dextran VH region significantly affects its affinity for antigen, however, an additional contribution of the altered amino acids to the differences in binding cannot be ruled out.
- Structure of the Carbohydrate Moieties on the Heavy Chain.
- Finally, glycohydrolase Endo H was used to investigate the structure of the VH oligosaccharide. The di-N-acetylchitobiose linkage of high mannose core oligosaccharides found on newly synthesized IgG H chains is susceptible to Endo H cleavage (11), while processed complex carbohydrates are resistant to Endo H cleavage. H chains obtained from cell cytoplasms were hydrolyzed by Endo H (data not shown). In contrast, heavy chains from the secretions of both THV8.3 and TKC3.2 were unaltered by Endo H treatment.
- Potential Significance of Carbohydrate in Antibody Function.
- Antibodies are glycoproteins with all heavy chains containing at least one and frequently several N-linked carbyhydrate residues (12). The role postulated for carbohydrate found on the heavy chain constant regions includes solubilization of the H chain, facilitation of subcellular transport and secretion, promotion of assembly, and maintenance of immunoglobulin conformational features which contribute to effector functions (13). Carbohydrate can also be found within the V region of an antibody molecule. Fifteen percent of human myeloma light chains have carbohydrate within their variable regions. (14). In a study of 76 human IgG myeloma proteins, approximately 25% were shown to contain a carbohydrate moiety on the Fab fragment (15). The carbohydrate was linked to either the light chains or the Fd fragments, and in a few cases to both.
- Experimental Discussion
- In the present invention it has been directly demonstrated that the presence of carbohydrate in CDR2 of VH is critical for the high affinity binding of a monoclonal antibody specific for polymeric alpha (1→6)-dextran and from this it can be inferred that the carbohydrate also contributes to the increased affinity for IM7. Thus not only the specific amino acid sequence of the variable region, but also its carbohydrate moieties can determine the specificity and magnitude of the antigen-antibody interaction.
- In an earlier study Matsuuchi et al. (16) isolated and characterized a spontaneously arising mutant of the myeloma J558 (IgA, lambda, anti-alpha (1→3) dextran) with decreased reactivity with polymeric dextran. The mutant differed from the wild-type in that it had increased amounts of sialic acid on the carbohydrate in its Fab region. Because the variable region of J558 does not contain the canonical carbohydrate addition sequence, the altered carbohydrate probably resides within the CH1 domain. The change in carbohydrate content was the consequence of the altered availability of cellular enzymes involved in glycosylation.
- Labeta et al. have reported that the affinity of an anti-DNP antibody for hapten DNP-GABA-BSA was significantly increased after Endo H cleavage of the Fab carbohydrate (17). In contrast and in accordance with the present invention the absence of carbohydrate from the fragment antigen binding (Fab) of an antibody to alpha (1→6)-dextran decreased the affinity of the antibody for antigen.
- Of great interest is the mechanism by which presence of an oligosaccharide attached to amino acids in the combining site of the antibody 14.6b.1 leads to increased Ka for both polymeric dextran and IM7. Both comparison with X-ray crystallographic studies of unrelated antibodies which predict that residues to which the carbohydrate is attached in VH should be exposed on the hypervariable loops and the Con A adsorption experiments of this invention, suggest that the VH oligosaccharide is relatively exposed and positioned at the surface of the Ig. Although sugar-sugar contacts between the two olibgosaccharides in CH2 of the constant region have been documented (18), it is difficult to see how direct interactions could occur both with polymeric dextran and a site filling oligosaccharide, IM7.
- A more likely explanation for the effect of glycosylation is that the carbohydrate linked to amino acid 58 alters the conformation of the combining site. Such alterations might increase the accessibility of the threonine residue at position 60 in the 14.6b.1 VH region so that it may contact the antibody more closely. Indeed, Feldman and coworkers have predicted from the hypothetical space-filling model of the V-region of the galactan-binding myeloma Ig J539 that H chain Thr residue 56 may contact galactan (19). The X-ray crystallographic structure of the 14.6b.1 Fab would aid in the understanding of how the presence of carbohydrate affects the topology of the combining site.
- Production of Antibodies With Altered Carbohydrate in Constant Region
- All four human IgG subclasses contain a consensus glycosylation sequence Asn-X-Thr/Ser (X—any amino acid) in the
C H2 domain. Several reports have indicated that this carbohydrate side chain is important for the effector functions of immunoglobulins, including Fc receptor binding and complement activation (22, 23). Site-directed mutagenesis was used to remove this carbohydrate addition signal from theC H2 domain so molecules deficient in carbohydrate, could be produced for use in assessing the role of carbohydrate in biological functions. Until now, researchers have used for this purpose immunoglobulins produced by cells grown in the presence of tunicamycin, an inhibitor of N-linked glycosylation. However, using that approach, only small quantities of protein could be produced, and it was difficult to assure that the resulting proteins were totally deficient in carbohydrate. - Many different approaches exist for site-directed mutagenesis; one approach used in the present invention is illustrated in FIG. 5 (24). The Sal I-Bam HI fragment containing the IgG constant region exon is cloned into the M13 phage M13mp19 at the polylinker site. The positive-strand DNA template of the recombinant phage is prepared by the standard polyethylene glycol method. Two primers are used to produce the mutation, one the M13 sequencing primer, the other a 5′ end-phosphorylated mutagenic primer with one nucleotide mismatched in the consensus glycosylation sequence. Both primers are annealed to the template at the same time. After primer extension and ligation, the mutant/wild-type-gapped heteroduplex is used to transformE. coli host JM109. To distinguish mutants from wild type phage clones, colony hybridization is employed. Under low stringency hybridization conditions, both the mutant and the wild type phage hybridize with the mutagenic oligomer. When the stringency of the hybridization conditions is increased, e.g., by increasing the temperature at which the hybridized phage plaques are washed, the labeled mutagenic oligomer remains hybridized with the mutant phage DNA but dissociates from the nonmutant phage DNA. Finally, the exact nucleotide change introduced into the immunoglobulin heavy chain must be confirmed by sequencing the DNA; the dideoxy method of sequencing is used (25, 26). The mutagenized gene is then transferred into an expression vector, where it can be used to direct the synthesis of an altered protein. This general approach can be used to introduce changes anywhere within the antibody molecule and may have particular application to the production of antibody molecules with altered idiotypes.
- Using the method described in this section, antibodies deficient in constant region carbohydrate have been produced. These exhibit altered effector functions: decreased ability to bind Fc receptors and activate complement. One (γ3) shows a decreased serum half-life in mice while the half life of the second (γ1) appears unchanged.
- This approach could also be used to put additional carbohydrate molecules in the constant region. This could be useful when ligands are attached to antibodies via their carbohydrate.
- 1. J. Sharon, E. A. Kabat, and S. L. Morrison,Molec. Immunol., 19, 389, (1982).
- 2. P. N. Alkolkar, S. K. Sikder, S. B. Bhattacharya, J. Liao, F. Gruezo, S. L. Morrison and E. A. Kabat,J. Immunol. 138, 4472, (1987)
- 3. G. M. Griffiths, C. Berek, M. Kaartinen, and C. Milstein,Nature (London) 312, 271, (1984).
- 4. V. T. Oi, S. L. Morrison, L. A. Herzenberg and P. Berg,Proc. Natl. Acad. Sci. U.S.A. 80, 825 (1983).
- 5. L. K. Tan, V. T. Oi, and S. L. Morrison,J. Immunol. 135, 3564, (1985).
- 6. E. W. Silverton, M. A. Navia, and D. R. Davis,Proc. Natl. Acad. Sci. U.S.A. 74, 5140, (1977).
- 7. D. R. Anderson, P. Samaraweera, and W. J. Grimes,Biochem. Biophys. Res. Commun. 116, 771, (1983).
- 8. A. D. Elbein,Trends in
Biochemical Sciences 6, 219 (1981). - 9. D. R. Anderson and W. J. Grimes,J. Biol. Chem. 257, 14858 (1982).
- 10. J. Sharon, E. A. Kabat and S. L., Morrison,Molec. Immunol. 18, 831, (1981).
- 11. P. W. Robbins, S. C. Hubbard, S. J. Turco and D. F. Wirth,Cell 12, 893 (1977).
- 12. C. Sidman,J. Biol. Chem. 256, 9374 (1981)
- 13. A. Shimizu, F. W. Putnam, C. Paul, J. R. Clamp. and I. Johnson,Nature New Biology 231, 73 (1971).
- 14. H. S. Sox, Jr. and L. Hood,Proc. Natl. Acad. Sci. U.S.A. 66, 975, (1970).
- 15. H. L. Spiegelberg, C. A. Abel, B. G. Fishkin, and H. M. Grey,Biochemistry 9, 4217 (1970).
- 16. L. Matsuuchi, L. A. Wims and S. L. Morrison,
Biochemistry 20, 4827, (1981). - 17. M. O. Labeta, R. A. Margni, J. Leoni, and R. A. Binaghi,Immunology 57, 311 (1986).
- 18. B. J. Sutton and D. C. Phillips,Biochem. Soc. Trans. 11, 130 (1983).
- 19. R. J. Feldmann, M. Potter, and C. P. J. Glaudemans,Molec. Immunol. 18, 683 (1981).
- 20. B. A. Newman and E. A. Kabat,J. Immunol. 135, 1220 (1985).
- 21. K. Takeo and E. A. Kabat,J. Immunol. 121, 2305, 1978.
-
- 23. J. Dangyl, T. Wensel, L. Stryer, S. L. Morrison, L. A. Herzenberg, and V. T. Oi, in press
- 24. S. L. Morrison,J. Immunol. 123, 793 (1979).
- 25. A. Nieto, A. Gaya, M. Jansa, and J. Vives,Molec. Immunol. 21, 537 (1984).
Claims (49)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/835,461 US20020028486A1 (en) | 1988-09-15 | 2001-04-16 | Antibodies having modified carbohydrate content and methods of preparation and use |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24474488A | 1988-09-15 | 1988-09-15 | |
US93855792A | 1992-08-28 | 1992-08-28 | |
US25152994A | 1994-05-31 | 1994-05-31 | |
US08/458,666 US6218149B1 (en) | 1988-09-15 | 1995-06-02 | Antibodies having modified carbohydrate content and methods of preparation and use |
US09/835,461 US20020028486A1 (en) | 1988-09-15 | 2001-04-16 | Antibodies having modified carbohydrate content and methods of preparation and use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/458,666 Division US6218149B1 (en) | 1988-09-15 | 1995-06-02 | Antibodies having modified carbohydrate content and methods of preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020028486A1 true US20020028486A1 (en) | 2002-03-07 |
Family
ID=22923952
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/458,666 Expired - Lifetime US6218149B1 (en) | 1988-09-15 | 1995-06-02 | Antibodies having modified carbohydrate content and methods of preparation and use |
US09/835,461 Abandoned US20020028486A1 (en) | 1988-09-15 | 2001-04-16 | Antibodies having modified carbohydrate content and methods of preparation and use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/458,666 Expired - Lifetime US6218149B1 (en) | 1988-09-15 | 1995-06-02 | Antibodies having modified carbohydrate content and methods of preparation and use |
Country Status (5)
Country | Link |
---|---|
US (2) | US6218149B1 (en) |
EP (1) | EP0359096B1 (en) |
JP (1) | JPH02231097A (en) |
AT (1) | ATE159982T1 (en) |
DE (1) | DE68928427T2 (en) |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050064514A1 (en) * | 2003-01-09 | 2005-03-24 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20050163783A1 (en) * | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
US20050215767A1 (en) * | 2002-08-14 | 2005-09-29 | Macrogenics Inc. | Fcgamma riib specific antibodies and methods of use thereof |
US20050260213A1 (en) * | 2004-04-16 | 2005-11-24 | Scott Koenig | Fcgamma-RIIB-specific antibodies and methods of use thereof |
US20060013810A1 (en) * | 2004-05-10 | 2006-01-19 | Johnson Leslie S | Humanized FcgammaRIIB-specific antibodies and methods of use thereof |
US20070036799A1 (en) * | 2005-08-10 | 2007-02-15 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20080044417A1 (en) * | 2006-05-26 | 2008-02-21 | Macrogenics, Inc. | Humanized Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof |
US20080044429A1 (en) * | 2006-06-26 | 2008-02-21 | Macrogenics, Inc. | Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof |
US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
US20080131435A1 (en) * | 2003-01-09 | 2008-06-05 | Macrogenics, Inc. | Identification and Engineering of Antibodies With Variant Fc Regions and Methods of Using Same |
US20080138349A1 (en) * | 2006-12-08 | 2008-06-12 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
WO2008157379A2 (en) | 2007-06-21 | 2008-12-24 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US20090017026A1 (en) * | 2002-08-14 | 2009-01-15 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US20090017027A1 (en) * | 2002-08-14 | 2009-01-15 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US20090053218A1 (en) * | 2002-08-14 | 2009-02-26 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US20090076251A1 (en) * | 2002-08-14 | 2009-03-19 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US20090074771A1 (en) * | 2002-08-14 | 2009-03-19 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US20090092610A1 (en) * | 2002-08-14 | 2009-04-09 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US20090098124A1 (en) * | 2006-03-10 | 2009-04-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
US20090162380A1 (en) * | 2005-01-05 | 2009-06-25 | Scott Glaser | Multispecific binding molecules comprising connecting peptides |
US20090191195A1 (en) * | 2006-06-26 | 2009-07-30 | Macrogenics, Inc. | Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof |
WO2009123894A2 (en) | 2008-04-02 | 2009-10-08 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
WO2009151717A2 (en) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
WO2010033279A2 (en) | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
WO2010080538A1 (en) | 2008-12-19 | 2010-07-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP2272533A1 (en) | 2003-01-13 | 2011-01-12 | MacroGenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
WO2011044368A1 (en) | 2009-10-07 | 2011-04-14 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
WO2011109400A2 (en) | 2010-03-04 | 2011-09-09 | Macrogenics,Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
EP2412728A2 (en) | 2004-08-03 | 2012-02-01 | Innate Pharma | Therapeutic and diagnostic methods and compositions targeting 4IG-B7-H3 and its counterpart NK cell receptor |
WO2012018687A1 (en) | 2010-08-02 | 2012-02-09 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US8216574B2 (en) | 2004-11-10 | 2012-07-10 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
WO2012162068A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
WO2014144763A2 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan Kettering Cancer Center | High affinity anti-gd2 antibodies |
WO2014159940A1 (en) | 2013-03-14 | 2014-10-02 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
WO2015184207A1 (en) | 2014-05-29 | 2015-12-03 | Macrogenics, Inc. | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
WO2016130539A2 (en) | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
EP3323830A1 (en) | 2010-06-19 | 2018-05-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
WO2018127787A1 (en) | 2017-01-06 | 2018-07-12 | Eutilex Co., Ltd. | Anti-human 4-1 bb antibodies and use thereof |
WO2018140026A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
US10100115B2 (en) | 2014-02-14 | 2018-10-16 | Macrogenics, Inc. | Methods for the treatment of vascularizing cancers |
EP3479844A1 (en) | 2005-04-15 | 2019-05-08 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
WO2019177970A1 (en) | 2018-03-12 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Bispecific binding agents and uses thereof |
US10501552B2 (en) | 2015-01-26 | 2019-12-10 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
US10501559B2 (en) | 2015-06-09 | 2019-12-10 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA |
US10626183B2 (en) | 2017-02-10 | 2020-04-21 | Eutilex Co., Ltd. | IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof |
US10717778B2 (en) | 2014-09-29 | 2020-07-21 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
US11053298B2 (en) | 2012-06-08 | 2021-07-06 | Eutilex Co., Ltd. | Epitope for switching to TH2 cell and use thereof |
US11072653B2 (en) | 2015-06-08 | 2021-07-27 | Macrogenics, Inc. | LAG-3-binding molecules and methods of use thereof |
US11078279B2 (en) | 2015-06-12 | 2021-08-03 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
WO2022153195A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8905669D0 (en) * | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6720165B2 (en) * | 2001-06-14 | 2004-04-13 | Zyomix, Inc. | Methods for making antibody fragments and compositions resulting therefrom |
WO2003025133A2 (en) * | 2001-09-14 | 2003-03-27 | Mimeon, Inc. | Methods of making glycolmolecules with enhanced activities and uses thereof |
ATE482235T1 (en) * | 2003-06-13 | 2010-10-15 | Biogen Idec Inc | AGLYCOSYL-ANTI-CD154 (CD40 LIGAND) ANTIBODIES AND USES THEREOF |
AU2004266159A1 (en) * | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
RS20070027A (en) | 2004-07-26 | 2008-11-28 | Biogen Idec Ma Inc., | Anti-cd154 antibodies |
MX2012011648A (en) | 2010-04-07 | 2012-11-29 | Momenta Pharmaceuticals Inc | High mannose glycans. |
CN103782168B (en) | 2011-03-12 | 2016-03-16 | 动量制药公司 | The N-comprising N-acetylhexosamine in glucoprotein product gathers candy |
UY34317A (en) | 2011-09-12 | 2013-02-28 | Genzyme Corp | T cell antireceptor antibody (alpha) / ß |
EP3617313A1 (en) * | 2011-10-05 | 2020-03-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain |
US9695244B2 (en) | 2012-06-01 | 2017-07-04 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
LT3495387T (en) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
SG11201506088RA (en) | 2013-03-11 | 2015-09-29 | Genzyme Corp | Hyperglycosylated binding polypeptides |
EP2855533A4 (en) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | Methods related to ctla4-fc fusion proteins |
EP2996772B1 (en) | 2013-05-13 | 2018-12-19 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
KR101815265B1 (en) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn specific human antibody and composition for treatment of autoimmune diseases |
US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
RS64072B1 (en) | 2014-03-19 | 2023-04-28 | Genzyme Corp | Site-specific glycoengineering of targeting moieties |
WO2016057769A2 (en) | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3883899T3 (en) * | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
-
1989
- 1989-09-05 DE DE68928427T patent/DE68928427T2/en not_active Expired - Fee Related
- 1989-09-05 EP EP89116368A patent/EP0359096B1/en not_active Expired - Lifetime
- 1989-09-05 AT AT89116368T patent/ATE159982T1/en not_active IP Right Cessation
- 1989-09-14 JP JP1239736A patent/JPH02231097A/en active Pending
-
1995
- 1995-06-02 US US08/458,666 patent/US6218149B1/en not_active Expired - Lifetime
-
2001
- 2001-04-16 US US09/835,461 patent/US20020028486A1/en not_active Abandoned
Cited By (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090017026A1 (en) * | 2002-08-14 | 2009-01-15 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US20050215767A1 (en) * | 2002-08-14 | 2005-09-29 | Macrogenics Inc. | Fcgamma riib specific antibodies and methods of use thereof |
US8530627B2 (en) | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8044180B2 (en) | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
EP2371389A2 (en) | 2002-08-14 | 2011-10-05 | MacroGenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
US20090092610A1 (en) * | 2002-08-14 | 2009-04-09 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US20090074771A1 (en) * | 2002-08-14 | 2009-03-19 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US20090076251A1 (en) * | 2002-08-14 | 2009-03-19 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US20090053218A1 (en) * | 2002-08-14 | 2009-02-26 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US7425619B2 (en) | 2002-08-14 | 2008-09-16 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US7425620B2 (en) | 2002-08-14 | 2008-09-16 | Scott Koenig | FcγRIIB-specific antibodies and methods of use thereof |
US20090017027A1 (en) * | 2002-08-14 | 2009-01-15 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US8003774B2 (en) | 2003-01-09 | 2011-08-23 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20050064514A1 (en) * | 2003-01-09 | 2005-03-24 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US9028815B2 (en) | 2003-01-09 | 2015-05-12 | Macrogenics, Inc. | Identification and engineering of antibodies with variant FC regions and methods of using same |
US20080138344A1 (en) * | 2003-01-09 | 2008-06-12 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
US20080131435A1 (en) * | 2003-01-09 | 2008-06-05 | Macrogenics, Inc. | Identification and Engineering of Antibodies With Variant Fc Regions and Methods of Using Same |
US8951517B2 (en) | 2003-01-09 | 2015-02-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8192737B2 (en) | 2003-01-09 | 2012-06-05 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2272533A1 (en) | 2003-01-13 | 2011-01-12 | MacroGenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
US20050163783A1 (en) * | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
US20090041758A1 (en) * | 2003-06-27 | 2009-02-12 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
US20050163782A1 (en) * | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
US8603473B2 (en) | 2003-06-27 | 2013-12-10 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
US20050260213A1 (en) * | 2004-04-16 | 2005-11-24 | Scott Koenig | Fcgamma-RIIB-specific antibodies and methods of use thereof |
US7521542B2 (en) | 2004-05-10 | 2009-04-21 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
US20060013810A1 (en) * | 2004-05-10 | 2006-01-19 | Johnson Leslie S | Humanized FcgammaRIIB-specific antibodies and methods of use thereof |
US8784808B2 (en) | 2004-05-10 | 2014-07-22 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US20090202537A1 (en) * | 2004-05-10 | 2009-08-13 | Macrogenics, Inc. | FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
US8133982B2 (en) | 2004-05-10 | 2012-03-13 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
EP2412728A2 (en) | 2004-08-03 | 2012-02-01 | Innate Pharma | Therapeutic and diagnostic methods and compositions targeting 4IG-B7-H3 and its counterpart NK cell receptor |
US8216574B2 (en) | 2004-11-10 | 2012-07-10 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
US8084026B2 (en) | 2005-01-05 | 2011-12-27 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
US20090162380A1 (en) * | 2005-01-05 | 2009-06-25 | Scott Glaser | Multispecific binding molecules comprising connecting peptides |
EP3479844A1 (en) | 2005-04-15 | 2019-05-08 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
US20070036799A1 (en) * | 2005-08-10 | 2007-02-15 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8217147B2 (en) | 2005-08-10 | 2012-07-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2573114A1 (en) | 2005-08-10 | 2013-03-27 | MacroGenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20090098124A1 (en) * | 2006-03-10 | 2009-04-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
US7786270B2 (en) | 2006-05-26 | 2010-08-31 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
US8216579B2 (en) | 2006-05-26 | 2012-07-10 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
US20080044417A1 (en) * | 2006-05-26 | 2008-02-21 | Macrogenics, Inc. | Humanized Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof |
US20090191195A1 (en) * | 2006-06-26 | 2009-07-30 | Macrogenics, Inc. | Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof |
US11098125B2 (en) | 2006-06-26 | 2021-08-24 | Macrogenics, Inc. | FcγRIIB-specific antibodies and methods of use thereof |
US8785599B2 (en) | 2006-06-26 | 2014-07-22 | Macrogenics, Inc. | FcγRIIB—specific antibodies and methods of use thereof |
US10100116B2 (en) | 2006-06-26 | 2018-10-16 | Macrogenics, Inc. | FcγRIIB-specific antibodies and methods of use thereof |
US20080044429A1 (en) * | 2006-06-26 | 2008-02-21 | Macrogenics, Inc. | Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof |
US8778339B2 (en) | 2006-06-26 | 2014-07-15 | Macrogenics, Inc. | Combination of FcγRIIB-specific antibodies and CD20-specific antibodies and methods of use thereof |
EP2505209A1 (en) | 2006-06-26 | 2012-10-03 | MacroGenics, Inc. | Fcgamma-RIIB-specific antibodies and methods of the use thereof |
US9737599B2 (en) | 2006-06-26 | 2017-08-22 | Macrogenics, Inc. | Combination of FcγRIIB-specific antibodies and CD20-specific antibodies and methods of use thereof |
US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
US11787871B2 (en) | 2006-12-08 | 2023-10-17 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for FcgammaRactivating and FegammaRinhibiting |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
US10711069B2 (en) | 2006-12-08 | 2020-07-14 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
US20080138349A1 (en) * | 2006-12-08 | 2008-06-12 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US9708408B2 (en) | 2006-12-08 | 2017-07-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc Regions with altered affinities for FcγRactivating and FcγRinhibiting |
WO2008157379A2 (en) | 2007-06-21 | 2008-12-24 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP3424951A1 (en) | 2007-06-21 | 2019-01-09 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
US9243069B2 (en) | 2008-04-02 | 2016-01-26 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using the same |
US8802093B2 (en) | 2008-04-02 | 2014-08-12 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
US10131713B2 (en) | 2008-04-02 | 2018-11-20 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
EP3045475A1 (en) | 2008-04-02 | 2016-07-20 | MacroGenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
US8669349B2 (en) | 2008-04-02 | 2014-03-11 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
WO2009123894A2 (en) | 2008-04-02 | 2009-10-08 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
US10479831B2 (en) | 2008-04-02 | 2019-11-19 | Macrogenics, Inc | BCR-complex-specific antibodies and methods of using same |
US11028183B2 (en) | 2008-04-02 | 2021-06-08 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
US8993730B2 (en) | 2008-04-02 | 2015-03-31 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
US20110097323A1 (en) * | 2008-04-02 | 2011-04-28 | Macrogenics, Inc. | Her2/neu-Specific Antibodies and Methods of Using Same |
US20110117089A1 (en) * | 2008-04-02 | 2011-05-19 | Macrogenics, Inc. | BCR-Complex-Specific Antibodies And Methods Of Using Same |
US9695236B2 (en) | 2008-04-02 | 2017-07-04 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
US9469692B2 (en) | 2008-04-02 | 2016-10-18 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
EP3067063A1 (en) | 2008-04-02 | 2016-09-14 | MacroGenics, Inc. | Her2/neu-specific antibodies and methods of using same |
WO2009151717A2 (en) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
US20110081347A1 (en) * | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
WO2010033279A2 (en) | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
WO2010080538A1 (en) | 2008-12-19 | 2010-07-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP2786762A2 (en) | 2008-12-19 | 2014-10-08 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
WO2011044368A1 (en) | 2009-10-07 | 2011-04-14 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
EP2982380A1 (en) | 2010-03-04 | 2016-02-10 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
WO2011109400A2 (en) | 2010-03-04 | 2011-09-09 | Macrogenics,Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US10730945B2 (en) | 2010-03-04 | 2020-08-04 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and users thereof |
US9714296B2 (en) | 2010-03-04 | 2017-07-25 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9714295B2 (en) | 2010-03-04 | 2017-07-25 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9896508B2 (en) | 2010-03-04 | 2018-02-20 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US10683364B2 (en) | 2010-03-04 | 2020-06-16 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9441049B2 (en) | 2010-03-04 | 2016-09-13 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
EP3323830A1 (en) | 2010-06-19 | 2018-05-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
EP4269563A2 (en) | 2010-06-19 | 2023-11-01 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
WO2012018687A1 (en) | 2010-08-02 | 2012-02-09 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2012162068A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
US11072646B2 (en) | 2012-06-08 | 2021-07-27 | Eutilex Co., Ltd. | Epitope for switching to TH1 cell and use thereof |
US11053298B2 (en) | 2012-06-08 | 2021-07-06 | Eutilex Co., Ltd. | Epitope for switching to TH2 cell and use thereof |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US9908938B2 (en) | 2013-03-14 | 2018-03-06 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
WO2014159940A1 (en) | 2013-03-14 | 2014-10-02 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
EP3839044A1 (en) | 2013-03-14 | 2021-06-23 | MacroGenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
US10730947B2 (en) | 2013-03-14 | 2020-08-04 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
US11421031B2 (en) | 2013-03-14 | 2022-08-23 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
WO2014144763A2 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan Kettering Cancer Center | High affinity anti-gd2 antibodies |
US10100115B2 (en) | 2014-02-14 | 2018-10-16 | Macrogenics, Inc. | Methods for the treatment of vascularizing cancers |
WO2015184207A1 (en) | 2014-05-29 | 2015-12-03 | Macrogenics, Inc. | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
EP3954703A2 (en) | 2014-05-29 | 2022-02-16 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
US10633440B2 (en) | 2014-05-29 | 2020-04-28 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens |
US11820818B2 (en) | 2014-05-29 | 2023-11-21 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
US11697684B2 (en) | 2014-05-29 | 2023-07-11 | Macrogenics, Inc. | Tri-specific binding molecules that specifically bind to multiple cancer antigens |
WO2015184203A1 (en) | 2014-05-29 | 2015-12-03 | Macrogenics, Inc. | Tri-specific binding molecules and methods of use thereof |
US10717778B2 (en) | 2014-09-29 | 2020-07-21 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
US10501552B2 (en) | 2015-01-26 | 2019-12-10 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
US10988534B2 (en) | 2015-02-09 | 2021-04-27 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof |
WO2016130539A2 (en) | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
US11858993B2 (en) | 2015-02-09 | 2024-01-02 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof |
US11858991B2 (en) | 2015-06-08 | 2024-01-02 | Macrogenics, Inc. | LAG-3-binding molecules and methods of use thereof |
US11072653B2 (en) | 2015-06-08 | 2021-07-27 | Macrogenics, Inc. | LAG-3-binding molecules and methods of use thereof |
EP4303235A2 (en) | 2015-06-08 | 2024-01-10 | MacroGenics, Inc. | Lag-3-binding moleculkes and methods of use thereof |
US11168150B2 (en) | 2015-06-09 | 2021-11-09 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA |
US10501559B2 (en) | 2015-06-09 | 2019-12-10 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA |
US11078279B2 (en) | 2015-06-12 | 2021-08-03 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
EP3456346A1 (en) | 2015-07-30 | 2019-03-20 | MacroGenics, Inc. | Pd-1 and lag-3 binding molecules and methods of use thereof |
US11623959B2 (en) | 2015-07-30 | 2023-04-11 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
EP3981792A1 (en) | 2015-07-30 | 2022-04-13 | MacroGenics, Inc. | Pd-1-binding molecules and methods of use thereof |
US10577422B2 (en) | 2015-07-30 | 2020-03-03 | Macrogenics, Inc. | PD-1-binding molecules and methods of use thereof |
US11840571B2 (en) | 2015-12-14 | 2023-12-12 | Macrogenics, Inc. | Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 |
US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
US11591400B2 (en) | 2016-04-15 | 2023-02-28 | Macrogenics, Inc. | B7-H3 directed antibody drug conjugates |
EP4032911A1 (en) | 2017-01-06 | 2022-07-27 | Eutilex Co., Ltd. | Anti-human 4-1bb antibodies and use thereof |
US11859004B2 (en) | 2017-01-06 | 2024-01-02 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
WO2018127787A1 (en) | 2017-01-06 | 2018-07-12 | Eutilex Co., Ltd. | Anti-human 4-1 bb antibodies and use thereof |
WO2018140026A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
US10626183B2 (en) | 2017-02-10 | 2020-04-21 | Eutilex Co., Ltd. | IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof |
EP3882271A2 (en) | 2017-02-10 | 2021-09-22 | Eutilex Co., Ltd. | Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof |
US10919976B2 (en) | 2017-02-10 | 2021-02-16 | Eutilex Co., Ltd. | IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof |
WO2019177970A1 (en) | 2018-03-12 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Bispecific binding agents and uses thereof |
WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
WO2022153195A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
Also Published As
Publication number | Publication date |
---|---|
DE68928427D1 (en) | 1997-12-11 |
DE68928427T2 (en) | 1998-06-04 |
JPH02231097A (en) | 1990-09-13 |
EP0359096A1 (en) | 1990-03-21 |
ATE159982T1 (en) | 1997-11-15 |
US6218149B1 (en) | 2001-04-17 |
EP0359096B1 (en) | 1997-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6218149B1 (en) | Antibodies having modified carbohydrate content and methods of preparation and use | |
Wallick et al. | Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen. | |
Tao et al. | Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. | |
US4935343A (en) | Monoclonal antibodies for interleukin-1β | |
KR101307614B1 (en) | Methods of purifying fc region containing proteins | |
JP2865645B2 (en) | Methods for producing chimeric antibodies | |
Yamaguchi et al. | Proteolytic fragmentation with high specificity of mouse immunoglobulin G mapping of proteolytic cleavage sites in the hinge region | |
EP2188306B1 (en) | Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such | |
CA2007336C (en) | Diagnostic test using chimeric antibodies | |
RU97100179A (en) | MONOCLONAL ANTIBODY AGAINST CD44V6 | |
Parkinson et al. | [23] Production and purification of antibodies against rat liver P450 enzymes | |
Woof et al. | The monocyte binding domain (s) on human immunoglobulin G | |
Borel et al. | Asymmetrically glycosylated IgG isolated from non-immune human sera | |
KR960002740B1 (en) | Anti-thrombin-binding substance monoclonal antibodies, hybridomas producing the same and the purification process and assay of thrombin-binding substance making use of said monoclonal antibodies | |
JPH10212299A (en) | Human nm protein, antibody against the same and cancer diagnostic | |
EP0449879A1 (en) | Heterobifunctional antibodies having specificity for platelets and thrombolytic agents | |
SHIMAMURA et al. | Analysis of Fc receptors for IgG on guinea pig peritoneal macrophages by the use of a monoclonal antibody to one of the Fc receptors | |
EP0415557B1 (en) | Separation of anti-metal chelate antibodies | |
Shigenori et al. | Hinge region of human IgG2 protein: conformational studies with monoclonal antibodies | |
MXPA01002248A (en) | High-affinity antibodies. | |
JP5492366B2 (en) | Carbohydrate-deficient transferrin (CDT) specific antibodies, their production and use | |
US5849499A (en) | Monoclonal antibody to acetylated lysine residues in recombinant bovine somatotropin | |
Kilchherr et al. | Activation of C1 by monoclonal antibodies directed against C1q | |
WO2019056991A1 (en) | Monoclonal antibody or antigen-binding fragment thereof and use of same | |
WO1997045451A1 (en) | Anti-human lect2 antibody, cells producing the same, and method and kit for assaying the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE;ASSIGNOR:COLUMBIA UNIVERSITY NEW YORK MORNINGSIDE;REEL/FRAME:021963/0021 Effective date: 20060727 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:COLUMBIA UNIVERSITY NEW YORK;REEL/FRAME:024684/0804 Effective date: 20060727 |